S90652 in Paediatric Hypertension
Information source: Servier
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Perindopril (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Institut De Recherche International Servier Official(s) and/or principal investigator(s):
Patrick Niaudet, Pr, Study Chair, Affiliation: Hôpital Necker Enfants Malades, Paris, France
Overall contact:
Patrick Niaudet, Pr, Phone: + 33 1 44 49 44 44
Summary
The aim of the study is to assess the long-term safety and effects on blood pressure of a
paediatric formulation of perindopril in hypertensive children
Clinical Details
Official title: Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children - 24 Months
Study design: Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Primary outcome: Clinical safety assessed from the patient's (parents) complaints and clinical follow-up
Secondary outcome: Blood pressure
Eligibility
Minimum age: 30 Months.
Maximum age: 17 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hypertensive children, who have been treated for four months at least with S90652,
with safety and efficacy
Exclusion Criteria:
- Poorly controlled hypertension
- Girls with signs of pubescence
Locations and Contacts
Patrick Niaudet, Pr, Phone: + 33 1 44 49 44 44
Hôpital Necker Enfants Malades, Paris, France; Recruiting
Patrick Niaudet, Pr, Phone: + 33 1 44 49 44 44
Additional Information
Starting date: November 2003
Last updated: September 12, 2005
|
